LSBCF — LakeShore Biopharma Co Share News
0.000.00%
Last trade - 00:00- $2.76m
- $59.77m
- CNY614.96m
Brief: LakeShore Biopharma Appoints Advisors to Special Committee Reviewing Takeover Bid
Brief: Lakeshore Biopharma Announces Receipt Of A Preliminary Non-Binding Proposal To Acquire The Company
Brief: Lakeshore Biopharma Expects 2026 Revenue To Be Between RMB550 Million And RMB650 Million
Brief: Lakeshore Biopharma Announces Us$15 Million Private Placement Financing
Brief: Lakeshore Biopharma Dave Chenn Resigned As Chairman
Brief: LakeShore Biopharma Announces Court Dismissal Of Former Chairman’s Injunction Applications
Brief: Lakeshore Biopharma Took Action To Remove Former Chairman In China Yi Zhang From All Executive Positions
Brief: LakeShore Biopharma Initiates Biologics License Application Of Pika Rabies Vaccine To The Drug Regulatory Authority Of Pakistan
Brief: LakeShore Biopharma Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Lakeshore Biopharma Granted Phase Iii Clinical Trial Approval To Explore Simplified Regimens For Ysja Rabies Vaccine
Brief: YS Biopharma Announces Name Change to LakeShore Biopharma
Brief: YS Biopharma To Hold EGM On May 21, 2024, Appoints Interim CEO
Brief: YS Biopharma Board Approves Appointment Of Dave Chenn As Interim CEO
Brief: YS Biopharma Granted Phase I Clinical Trial License Of Therapeutic Chronic Hepatitis B Virus Vaccine
Brief: YS Biopharma Announces Interim Results Of Late-Stage Clinical Study Of PIKA Rabies Vaccine
Brief: YS Biopharma Announces Full Repayment Of US$40,000,000 Loan Facility
U.S. STOCKS ON THE MOVE-Lands' End, Energy sector
U.S. STOCKS ON THE MOVE-Biogen, NetApp, LyondellBasell
U.S. STOCKS ON THE MOVE-Monopar Therapeutics, Molecular Templates, NRG Energy